April 1, 2026 - 17:45

A St. Louis hospital is now offering a groundbreaking medical technology that destroys tumors without a single surgical cut. The facility is among the first in the nation to adopt the Edison Histotripsy System, a non-invasive procedure that represents a significant leap forward in patient care.
This innovative technology utilizes focused sound waves, or ultrasound energy, to precisely target and mechanically disintegrate unwanted tissue within the body. The process leaves the treated cells as a liquid acellular slurry, which the body then naturally absorbs and clears away. Because it requires no incisions, the procedure dramatically reduces risks associated with traditional surgery, such as infection, bleeding, and lengthy recovery times.
The introduction of histotripsy offers new hope, particularly for patients with liver tumors who may not be ideal candidates for conventional surgery. The precision of the sound waves helps spare healthy surrounding tissue, aiming for fewer complications and a much faster return to daily life for patients. Hospital officials emphasize that this advancement underscores their commitment to providing leading-edge, minimally invasive treatment options, potentially changing the standard of care for certain oncology patients.
September 30, 2026 - 21:59
Micron Technology Tops Lofty Fiscal Q4 Goals, Guides Above ViewsMicron Technology exceeded analyst expectations for its fiscal fourth quarter, delivering results that outperformed even the most optimistic projections on Wall Street. The memory chip maker...
September 30, 2026 - 01:50
Space Force Turns to Laser Systems to Shield Launch Sites from Drone ThreatsThe U.S. Space Force is moving forward with plans to deploy laser technology as part of a broader effort to defend its launch facilities from unauthorized drones. The initiative focuses on...
September 29, 2026 - 04:58
DIU Seeks Investors in Counter-Unmanned Systems TechnologyThe Defense Innovation Unit is looking for private investors to back companies working on counter unmanned systems technology. The effort targets firms building tools to detect, track, and disable...
September 28, 2026 - 02:02
Novo Nordisk (CPSE:NOVO B) Secures Long-Acting Injectable Technology In €1.165 Billion Nanexa Licensing AgreementNovo Nordisk has entered a global licensing agreement with Swedish drug delivery company Nanexa, valued at up to 1.165 billion euros. The deal centers on Nanexa`s PharmaShell technology, a platform...